U.S. Markets closed
  • S&P Futures

    3,603.50
    +27.50 (+0.77%)
     
  • Dow Futures

    29,811.00
    +265.00 (+0.90%)
     
  • Nasdaq Futures

    11,970.25
    +65.00 (+0.55%)
     
  • Russell 2000 Futures

    1,838.40
    +21.30 (+1.17%)
     
  • Crude Oil

    43.47
    +0.41 (+0.95%)
     
  • Gold

    1,821.50
    -16.30 (-0.89%)
     
  • Silver

    23.42
    -0.22 (-0.92%)
     
  • EUR/USD

    1.1850
    +0.0004 (+0.0355%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3328
    +0.0006 (+0.0466%)
     
  • USD/JPY

    104.5510
    +0.0630 (+0.0603%)
     
  • BTC-USD

    18,291.54
    -40.96 (-0.22%)
     
  • CMC Crypto 200

    367.64
    +6.21 (+1.72%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,226.73
    +699.36 (+2.74%)
     

Infinity Pharmaceuticals to Present Corporate Overview at 38th Annual J.P. Morgan Global Healthcare Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals, will provide a corporate overview at the 38th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 9:00 am Pacific Time at the Westin St. Francis Hotel in San Francisco, California.

A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.

About Infinity and IPI-549

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-1 is an ongoing Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab) in approximately 225 patients with advanced solid tumors including patients refractory to anti-PD-1 therapy. MARIO-275 and MARIO-3 have recently initiated. MARIO-275 is a global, randomized, combination study of IPI-549 combined with Opdivo in I/O naïve urothelial cancer patients. MARIO-3 is the first IPI-549 combination study in front-line advanced cancer patients and is evaluating IPI-549 in combination with Tecentriq and Abraxane in front-line TNBC and in combination with Tecentriq and Avastin in front-line RCC. With the MARIO-275, MARIO-3 and the MARIO-1 studies, Infinity is evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005204/en/

Contacts

Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com